This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Ghayour-Mobarhan, M. Articles by Ferns, G. A. A. Search for Related Content PubMed PubMed Citation Articles by Ghayour-Mobarhan, M. Articles by Ferns, G. A. A. Social Bookmarking                   What's this?

Heat Shock Protein Antibody Titers Are Reduced by Statin Therapy in Dyslipidemic Subjects: A Pilot Study

Centre for Clinical Science and Measurement, School of Biomedical and Molecular Science, University of Surrey, Guildford

D. J. Lamb, PhD

Centre for Clinical Science and Measurement, School of Biomedical and Molecular Science, University of Surrey, Guildford

N. Vaidya, MD

Department of Clinical Biochemistry, The Royal Surrey County Hospital, Guildford, Surrey, UK

C. Livingstone, MRCPath

Department of Clinical Biochemistry, The Royal Surrey County Hospital, Guildford, Surrey, UK

T. Wang, MRCPath

Department of Clinical Biochemistry, The Royal Surrey County Hospital, Guildford, Surrey, UK

G. A. A. Ferns, MD, DSc

Centre for Clinical Science and Measurement, School of Biomedical and Molecular Science, University of Surrey, Guildford, Department of Clinical Biochemistry, The Royal Surrey County Hospital, Guildford, Surrey, UK, g.ferns{at}surrey.ac.uk

Antibody titers to heat shock protein (Hsp)-60 and -65 are positively related to risk of vascular disease and cardiovascular endpoints. There are few data on the factors that regulate the levels of these antibodies. It is known that the statins have antiinflammatory and immunoregulatory properties. The authors examined the effects of 2 statins, simvastatin (Zocor^®) and atorvastatin (Lipitor^®) on antibody titers to Hsp-60, -65, and -70 in a group of dyslipidemic patients. Twenty patients attending a lipid clinic, and previously not receiving lipid-lowering treatment, were treated with 10 mg of simvastatin (n=11) or atorvastatin (n=9) for 4 months. An additional 14 patients were recruited from the same clinic at the same hospital as a control group. The medication of these latter patients was unaltered for 4 months and the same parameters were measured as for the statin group. Antibody titers to Hsp-60, -65, and -70 were measured by enzyme-linked immunosorbent assay and lipoprotein profile and highly sensitive serum C-reactive protein (CRP) were measured by routine methods before and after treatment. Pretreatment and posttreatment data were compared by paired t or Mann-Whitney tests. Overall statin treatment was associated with a significant reduction in median antibody titers to Hsp-60 (17.2%, p=0.03), Hsp-65 (15.9%, p=0.003) and Hsp-70 (8.3%, p=0.006), but not in control patients. Both statins caused a reduction in median serum CRP concentrations (45% overall, p<0.05), but significant changes were not observed in the control patients. The effects on Hsp antibody titers were not related to changes in serum CRP concentrations (p>0.05). However, there was a significant correlation between changes in antibody titers to Hsp-60 vs Hsp-65 (p<0.01), Hsp-60 vs Hsp-70 (p<0.05), and Hsp-65 vs Hsp-70 (p<0.001). Statin treatment was associated with a reduction in antibody titers to Hsp-60, -65, and -70. This reduction is not fully explained by the antiinflammatory effects of the statins but may be due to their other immunomodulatory properties.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?